Cancer Anorexia-Cachexia Syndrome Drug Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Cancer Anorexia-Cachexia Syndrome Drug Market is segmented By Product Type (Progestogens, Corticosteroids, Combination therapies, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Cancer Anorexia-Cachexia Syndrome Drug Market is expected to grow at a high CAGR during the forecasting period (2024-2031).

Cancer anorexia-cachexia syndrome (CACS) is a multifactorial syndrome defined as a progressive wasting disorder.  Loss of both skeletal muscle and fat distinguishes it from starvation. It incorporates a complex metabolic syndrome with abnormal carbohydrate, protein and lipid metabolism. Some progress has been made in understanding multifactorial pathophysiology. Although incompletely understood, the cancer syndrome is likely to arise from imbalanced interactions between inflammatory cytokines, neuropeptides, hormones and tumor-derived products.

Cancer Anorexia-Cachexia Syndrome Drug Market Scope

For More Insights Request Free Sample

Cancer Anorexia-Cachexia Syndrome Drug Market Dynamics

The increasing burden of cancer cases worldwide also increases the prevalence of cancer cachexia among cancer patients, which is characterized by systemic inflammation, harmful protein and energy balance, and an involuntary loss of lean body mass. Because of this factor, most of the major players are focused on R&D activities to develop highly effective novel drugs in the treatment of cancer cachexia are expected to drive the market. 

The increasing prevalence of Cancer Cases, coupled with the increased incidence of cachexia is expected to drive the global Cancer Anorexia-Cachexia Syndrome Drug market during the forecast period.

As per the World Health Organisation (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to the data published by the society on CACS in 2018 it was estimated that 0.5-1% of the total population were suffering from cancer-induced cachexia. This number has led to an increase in the adoption of cancer cachexia drugs.

The presence of potential drugs in the clinical pipeline is expected to drive the global Cancer Anorexia-Cachexia Syndrome Drug market during the forecast period.

At present, the treatment options for cachexia among cancer patients are very limited to drugs like progestogens, corticosteroids, NSAIDS and others. These drugs proved their efficacy, but at present, no drug is specifically approved for this condition to treat. Thus, the demand for significant market players is increasing to fulfil through R&D and novel drugs in the market. For instance, to study the safety of APD209 in patients with advanced malignancy and active cachexia by Acacia Pharma Ltd is currently under phase 2 clinical trials.

The high cost associated with treatment is likely to hinder the market growth.

Apart from the increasing prevalence of cancer anorexia cachexia globally, certain other factors that are limiting the growth of the market were the high cost of treatment as well as limited reimbursement policies and also stringent government regulations. For instance, As per the data published in PubMed.gov and National Library of Medicine NIH, the cost of inpatient was significantly higher in cachexia than non-cachexic lung cancer patients, $13,560 and $13 190. In general, the cost of cachexic and non-cachexic cancer patients is about 14 751 and 13 928 has been the major factor hampering the market growth.

COVID-19 Impact on Cancer Anorexia-Cachexia Syndrome Drug Market

Due to the covid-19 pandemic outbreak, the market for Global Cancer Anorexia-Cachexia Syndrome Drug Market was seen to be raised slightly, As per the research article published in the British Journal of Nutrition, 2020, changes in the nutritional status and weight loss during hospitalization are primarily reported in some populations, but it is not entirely in COVID-19 patients. But the symptoms and associated conditions of COVID-19 lead to nutritional status deterioration, leading to cachexia and also, cancer patients are at a higher risk of being infected with COVID-19, as they are immunocompromised and their ability to fight against the infection is very low compared to others, leading to the higher chances of developing multiple organ-related complications or cachexia.

Cancer Anorexia-Cachexia Syndrome Drug Market Segment Analysis

Based on Product Type, the global Cancer Anorexia-Cachexia Syndrome Drug market is segmented into Progestogens, Corticosteroids, Combination therapies, Others

Progestogens

The progestogens segment dominates the market due to a comparatively low cost of progestogens and high bioavailability and high efficacy in the cancer anorexia cachexia treatment. Many placebo-controlled, double-blind clinical trials have demonstrated that progestational agents, such as megestrol (Megace) and medroxyprogesterone, can lead to appetite stimulation and weight gain in patients with cancer-anorexia and cachexia. As per the data published in the cancer network in the United States, an Oral formulation of megestrol is considerably less expensive that is $35 than the liquid form and also has fewer side effects than corticosteroids.

Corticosteroids 

Corticosteroids are the first agents to undergo placebo-controlled, double-blind evaluation for possible use in cancer cachexia. The first such trial, conducted in the 1970s by Moertel and colleagues at the Mayo Clinic, demonstrated that corticosteroids could stimulate appetite in patients with advanced, incurable cancer. Dexamethasone (3 to 8 mg/d) is a reasonable option for clinical use. Known detriments to corticosteroid use include the well-known toxicities associated with long-term administration, including myopathy, peptic ulcer disease, infection, adrenal suppression, and hyperglycemia. However, many patients with advanced cancer anorexia and cachexia do not survive long enough to suffer from these toxicities.

Combination therapies

Amino acid supplements, particularly glutamine, L-Carnitine and L arginine, and these amino acids are being evaluated in combination with metoclopramide, oxandrolone (Oxandrin) to assess their potential benefit.

Based on the Distribution channel, the hospital pharmacy is expected to dominate the Global Cancer Anorexia-Cachexia Syndrome Drug market during the forecast period 

The hospital pharmacies held the largest share in the global Cancer Anorexia-Cachexia Syndrome Drug market. This is mainly owing to the increasing number of patients suffering from cancers and other conditions like cachexia which are treated in hospitals equipped with advanced infrastructure and adequate facilities and with potential drugs. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Cancer Anorexia-Cachexia Syndrome Drug Market Geographical Share

North America region holds the largest market share of the global Cancer Anorexia-Cachexia Syndrome Drug

North America is expected to hold a large market share in the global Cancer Anorexia-Cachexia Syndrome Drug Market due to the growing incidence of cancer cases.  The International Agency for Research on Cancer (IARC) claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel products, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to the increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, in march 2019, Helsinn Healthcare S.A announced the drug Anamorelin undergoing Phase 3 trials to evaluate the effect in Cancer Anorexia Cachexia in Non-Small Cell Lung Cancer patients.

Cancer Anorexia-Cachexia Syndrome Drug Market Companies and Competitive Landscape 

The Global Cancer Anorexia-Cachexia Syndrome Drug Market is moderately competitive with some key competitors like Pfizer Inc, Helsinn Healthcare, Acacia Pharma Ltd, PsiOxus Therapeutics Ltd, Incyte Corp, Aeterna Zentaris Inc, Obexia AG, Aphios Corporation, Merck & Co, Novartis AG. The growth of these companies is attributed to product launch, acquisition of independent companies and investments in multiple sectors. For instance, OHR/AVR118 studied by Ohr Pharmaceutical Inc is currently under Phase 2 trials for open-label study in advanced cancer cachexia patients.

Pfizer Inc.  

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

PF-06946860, sponsored by Pfizer Inc., is currently under Phase I clinical trials. The purpose of this trial is to determine the safety of PF-06946860 in the treatment of colorectal cancer, non-small-cell lung cancer, Pancreatic cancer, cachexia.

Key developments:

In July 2019- Pfizer Inc. agreed with Mylan to create a new global pharmaceutical company, Viatris to expand its global reach, strengthen its market position.

Why Purchase the Report?

• Visualize the composition of the Global Cancer Anorexia-Cachexia Syndrome Drug Market segmentation by Test Type, by Cancer Type, by End-User and by Region.
• Identify commercial opportunities in Global Cancer Anorexia-Cachexia Syndrome Drug Market by analyzing trends and co-development deals. 
• Excel data sheet with thousands of data points of Global Cancer Anorexia-Cachexia Syndrome Drug Market-level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. 
• Disorder mapping in excel for the key Disorder of all major market players

The Global Cancer Anorexia-Cachexia Syndrome Drug Market report would provide access to an approx.  market data 53 tables, 44 figures and 180 pages. 

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers